Reactogenicity and immunogenicity against MPXV of the intradermal administration of 1 Modified Vaccinia Ankara compared to the standard subcutaneous route. 2

3

4	Valentina Mazzotta ¹ , Pierluca Piselli ^{2*} , Alessandro Cozzi Lepri ³ , Giulia Matusali ⁴ , Eleonora Cimini ⁵ ,										
5	Rozenn Esvan ¹ , Francesca Colavita ⁴ , Roberta Gagliardini ¹ , Stefania Notari ⁵ , Alessandra Oliva ¹ ,										
6	Silvia Meschi ⁴ , Rita Casetti ⁵ , Giulia Micheli ¹ , Licia Bordi ⁴ , Alessandro Giacinta ¹ , Germana Grassi ⁵ ,										
7	Saba Gebremeskel Tekle ¹ , Claudia Cimaglia ² , Jessica Paulicelli ¹ , Alessandro Caioli ² , Paola Galli ⁶ ,										
8	Giulia Del Duca ¹ , Miriam Lichtner ⁷ , Loredana Sarmati ⁸ , Enrica Tamburrini ^{9,10} , Claudio										
9	Mastroianni ¹¹ , Alessandra Latini ¹² , Paolo Faccendini ¹³ , Carla Fontana ¹⁴ , Emauele Nicastri ¹ , Andrea										
10	Siddu ¹⁵ , Alessandra Barca ¹⁶ , Francesco Vaia ¹⁵ , Enrico Girardi ¹⁷ , Fabrizio Maggi ⁴ , Andrea Antinori ¹ ,										
11	for the MPOX Vaccine Lazio Study Group.										
12											
13	¹ Clinical Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro										
14 15	 Spallanzani IRCCS, Rome, Italy; ² Clinical Epidemiology Unit, National Institute for Infectious Diseases Lazzaro Spallanzani 										
16	IRCCS, Rome, Italy;										
17	³ Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for										
18	Global Health, UCL, London, UK;										
19	⁴ Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS,										
20	Rome, Italy;										
21	⁵ Cellular Immunology and Pharmacology Laboratory, National Institute for Infectious Diseases,										
22	Lazzaro Spallanzani IRCCS, Rome, Italy; ⁶ Health Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome										
23 24	⁶ Health Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy;										
25	⁷ Infectious Diseases Unit, Santa Maria Goretti Hospital of Latina, NESMOS Department,										
26	Sapienza University of Rome, Italy;										
27	⁸ Infectious Diseases Unit, Tor Vergata University Hospital, Rome, Italy;										
28	⁹ Department of Safety and Bioethics, Catholic University of the Sacred Heart, Rome, Italy;										
29	¹⁰ Infectious Diseases Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy;										
30	¹¹ Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy;										
31	¹² STI/HIV Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy.										
32	¹³ Pharmacy Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome,										
33 34	Italy; ¹⁴ Laboratory of Microbiology and Biological Bank Unit, National Institute for Infectious Diseases										
34 35	Laboratory of Microbiology and Biological Bank Onit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy;										
36	¹⁵ General Directorate of Prevention, Ministry of Health, Rome, Italy;										
37	¹⁶ Unit of Health Promotion and Prevention, Directorate of Health and Integration, Lazio Region,										
38	Rome, Italy;										
39	17 Notientificep Directionen Nationals hastituten formila footiousieDiscasard Lauzawa (SpadamzaniralReCCS,										
40	Rome, Italy.										

41

*Corresponding author 42

- Pierluca Piselli, MSc MPH 43
- 44 e-mail: pierluca.piselli@inmi.it
- Clinical Epidemiology Unit 45
- National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS 46
- Via Portuense 292, 00149 Rome, Italy 47

48 Abstract

49 The recent resurgence of Mpox in central Africa has been declared again a Public Health Emergency 50 of International Concern (PHEIC) requiring coordinated international responses. Vaccination is a priority to expand protection and enhance control strategies, but the vaccine's need exceeds the 51 currently available doses. Intradermal administration of one-fifth of the standard Modified-Vaccinia-52 53 Ankara (MVA-BN) dose was temporarily authorized during the 2022 PHEIC. Studies conducted 54 before 2022 provided evidence about the humoral response against the Vaccinia virus (VACV) after 55 vaccination but not against the Mpox virus (MPXV). Moreover, no data are available on the T-cell response elicited by MVA-BN administered subcutaneously or intradermally. Here, we compare the 56 two vaccine administration routes according to reactogenicity and immunogenicity based on data 57 58 from 943 vaccine recipients during the 2022 vaccination campaign in Rome, Italy. We found that the 59 intradermal route elicited slightly higher titers of MPXV-specific IgG and nAbs than the subcutaneous one. At the same time, no differences in cellular response were detected. MVA-BN was 60 globally well tolerated despite higher reactogenicity for the intradermal than the subcutaneous route, 61 62 especially for the reactions at the local injection site. The intradermal dose-sparing strategy was 63 proven safe and immunogenic and would make vaccination available to more people.

64

65

66 Introduction

As of May 2022, an unexpected mpox epidemic caused by the clade IIb spread in 122 countries with a global case count higher than 99.000¹. The rapid increase in confirmed cases led to the subsequent declaration of mpox as a public health emergency of international concern (PHEIC) by the World Health Organization (WHO)². Therefore, the WHO recommended vaccination for high-risk people and other mitigation strategies to control the epidemic³.

Licensed vaccines against mpox consist of two doses of the third-generation replication-deficient
 modified vaccinia Ankara produced by Bavarian Nordic (MVA-BN)^{4,5}. The standard route of
 administration of MVA-BN is subcutaneous (SC), with two doses delivered at least 28 days apart.

However, a randomized clinical trial (RCT) compared the safety and immunogenicity of the standard SC formulation (dose and route) of MVA-BN with the intradermal (ID) administration of one-fifth of the standard SC dose⁶. Although the proportion of local reactions was significantly higher after ID inoculation than SC, the ID route was considered non-inferior to the SC route regarding neutralization against vaccinia virus, and it was purposed as a valid alternative in the event of an emergency requiring more doses available⁷.

81 In the summer of 2022, it became necessary to rapidly vaccinate as many high-risk people as possible 82 to contain the epidemic ⁸. Therefore, due to the limited availability of MVA-BN worldwide, the 83 European Medicine Agency and Food and Drugs Administration authorized using the intradermal 84 route of administration with a reduced dose to extend vaccination ^{9,10}.

Data from large-scale administration of MVA-BN published by Bavarian Nordic confirmed the overall safety of the vaccine with an increased frequency of syncopal events after ID administration¹¹. Recently, Frey et al. reported data from a phase-2 open-label trial comparing two 2-dose ID regimens of MVA-BN (one-tenth and one-fifth) with the standard dose SC regimen. MVA-BN administrated ID at fractional doses was safe, and the vaccination with one-fifth (but not one-tenth) dose demonstrated non-inferior immunogenicity by vaccinia virus (Western Reserve strain) plaque reduction neutralization test (PRNT) after 43 days¹². However, even though similar clinical

92 effectiveness of the two different vaccination schedules against mpox was reported from 2022 real93 world data¹³, comparative data on the immunogenicity of ID route compared to SC are lacking and,
94 those available are not informative on the humoral response specifically against mpox, nor on the T95 cell response.

Although the massive vaccination campaigns during the MPXV Clade IIb outbreak must have helped 96 to control the epidemic in high-income countries¹⁴, many outbreaks were constantly observed in 97 endemic areas during the last year, especially in South Africa, where Clade IIb of mpox virus 98 (MPXV) was still detected¹⁵ and in the Democratic Republic of Congo, where the Clade I had 99 acquired the capability of human-to-human transmission through the sexual route¹⁶, and it has spread 100 101 in some neighboring countries where mpox cases have never been reported before (e.g Burundi, Rwanda, and Uganda)¹⁷. Furthermore, this "new sexually transmitted clade", named Clade Ib, is 102 particularly worrisome because of its lethality (nearly 3%)¹⁸, leading WHO to renew the declaration 103 104 of mpox as a PHEIC on the 14th of August 2024¹⁷.

Vaccination is recommended as one of the main tools to control this new increase in mpox cases. 105 106 WHO and the African Centers for Disease Control and Prevention (CDC) are producing efforts to 107 step up the vaccination campaign in low-income countries with limited access. In front of the 10 108 million doses African CDC estimates are needed to contain the current outbreak, the negotiations with Bavarian Nordic aim to obtain around 200.000 doses of MVA-BN¹⁹. In this setting, enhancing 109 knowledge about the reactogenicity and immunogenicity against MPXV of the intradermal dose-110 sparing strategy compared to the standard subcutaneous one in mpox high-risk people in the real-111 112 world setting is crucial to address an efficient and cost-effective implementation of the arising mpox vaccination campaign. 113

Here, we report observational data from a data set on the non-randomized comparison on safety and reactogenicity, and immunogenicity (neutralization and T-cell response) specifically directed against the MPXV target between the two vaccination schedules of MVA-BN (Jynneos) delivered in the vaccination campaign during the 2022-2023 mpox outbreak in Italy.

- 5 -

118 Methods

119 Patients' enrolment

In the Lazio Region of Italy mpox vaccination campaign started on August 8th, 2022, and took place
in a hospital setting at the Lazzaro Spallanzani National Institute for Infectious Diseases in Rome,
which was identified as the only vaccination center in the entire region.

According to the recommendations of the Ministry of Health²⁰, MVA-BN was administered as pre-123 124 exposure prophylaxis to a target population, including laboratory personnel with possible direct exposure to orthopoxviruses (OPXV) and high-risk gay-bisexual-men who have sex with men 125 (GBMSM), defined as individuals reporting a recent history of sexually transmitted infections (STIs), 126 127 multiple sexual partners or participation in group sex events, sexual encounters in clubs/cruising/saunas or sexual acts associated with the use of Chemical drugs (Chemsex). For 128 individuals who had never received the smallpox vaccine (vaccine-naïve or non-primed), the 129 130 vaccination schedule consisted of a two-dose cycle with a 28-day interval between each dose, while individuals who had received the smallpox vaccine in the past (vaccine-experienced or primed) were 131 administered a single-dose cycle. Of note, in Italy, the smallpox vaccination campaign was stopped 132 133 in 1977 and officially abrogated in 1981²¹.

134 The MVA-BN first dose was administered subcutaneously during the first two weeks of the 135 vaccination campaign, after which the intradermal route was adopted, following the ministerial 136 indications²².

For the same reason, the vaccine was administered exclusively intradermically in those receiving a
second dose. A prospective observational cohort was integrated into the framework of this vaccination
campaign.

140

141 *Study protocol*

The protocol for the study named Mpox-Vac ("Studio prospettico osservazionale per monitorare
aspetti relativi alla sicurezza, all'efficacia, all'immunogenicità e all'accettabilità della vaccinazione

anti Monkeypox con vaccino MVA-BN (JYNNEOS) in persone ad alto rischio") was approved by
the INMI Lazzaro Spallanzani Ethical Committee (approval number 41z, Register of Non-Covid
Trials 2022). The study protocol was previously described in detail ²³.

147

Briefly, all subjects eligible for mpox vaccination according to the ministerial guidelines and who 148 signed a written informed consent were enrolled in the study. Laboratory personnel were excluded 149 150 from the analysis. At baseline (when receiving the first MVA-BN dose, T1), subjects were evaluated for demographic and behavioural characteristics linked to mpox exposure. Information regarding HIV 151 status, CD4 count, HIV pre-exposure prophylaxis (PrEP) uptake and any history of previous STIs 152 153 was collected. Other time points were scheduled at the administration of the second dose (T2) and one month after the completion of the cycle (T3). For the vaccine-experienced individuals (primed) 154 who received a single-dose schedule as a complete vaccination cycle, T2 was the time point 155 156 corresponding to one month after vaccination completion.

157

158 Assessment of adverse reactions

As part of the protocol, participants were delivered a paper symptoms diary after each vaccine dose (T1 and T2) to collect self-reported adverse effects following immunization (AEFIs) for 28 consecutive days. Participants returned the completed diaries at the next time point.

Participants were able to report the presence of systemic symptoms (S-AEFIs) classified as fatigue, 162 muscle pain, headache, gastrointestinal effects, and chills, and local injection site symptoms (LIS-163 164 AEFIs), such as redness, induration, and pain. AEFIs were graded by the vaccinees as absent (grade 0), mild (1), moderate (2), or severe (3). Here, we report the results regarding erythema and induration 165 166 as recalculated with the use of the current FDA Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. According to that scale, a 167 diameter of 25 to 50 mm indicates a mild reaction, 51 to 100 mm is a moderate reaction, and more 168 than 100 mm is a severe reaction²⁴. 169

170

171 Assessment of immunogenicity

172 In a specific subgroup of participants for whom blood samples collected at each time point were

available, the assessment of the early humoral and cellular immune response was performed.

174 MPXV-specific IgG and neutralization assays

Specific anti-MPXV immune response was evaluated by measuring MPXV-specific IgGs and 175 neutralizing antibodies in the serum as previously described²⁵. The presence of anti-MPXV IgGs was 176 assessed on immunofluorescence slides in-house prepared with Vero E6 cells (ATCC) infected with 177 an MPXV isolated from the skin lesion of a patient infected with MPXV during the 2022 outbreak 178 179 (GenBank: ON745215.1, referred to the clinical sample). Serum samples were tested with a starting dilution of 1:20, and serial two-fold dilutions were performed to determine anti-MPXV IgG titer. 180 MPXV-specific neutralizing antibodies (nAbs) were measured by 50% plaque-reduction-181 182 neutralization test (PRNT₅₀) with a starting dilution of 1:10. Specifically, serum samples were heatinactivated at 56 °C for 30 min and titrated in duplicate in 4 four-fold serial dilutions. Each serum 183 184 dilution was added to the same volume (1:1) of a solution containing 100 TCID50 MPXV isolate (GenBank: ON745215.1, referred to the clinical sample) and incubated at 37 °C for 2 h. Subconfluent 185 Vero E6 cells were infected with virus/serum mixtures and incubated at 37 °C and 5% CO₂. After 5 186 187 days, the supernatant was carefully discarded, and a crystal violet solution (Diapath S.P.A.) containing 10% formaldehyde (Sigma-Aldrich) was added for 30 min, then cells were washed with phosphate-188 buffered saline (PBS, 1X; Sigma-Aldrich). Using the Cytation 5 reader (Biotek), the number of 189 190 plaques was counted. The neutralizing titers were estimated by measuring the plaques number reduction as compared to the control virus wells. The highest serum dilution showing at least 50% of 191 192 the plaque number reduction was indicated as the 50% neutralization titer (PRNT₅₀). Each test included serum control (1:10 dilution of each sample tested without virus), cell control (Vero E6 cells 193 alone), and virus control (100 TCID₅₀ MPXV in octuplicate). 194

195

196 *PBMC isolation*

Using Ficoll density gradient centrifugation (Pancoll human, PAN Biotech) methodperipheral blood
mononuclear cells (PBMC) were isolated, frozen in FBS (Fetal Bovine Serum, Gibco, USA) added
of 10% of DMSO (Merck Life sciences, Milan, Italy) at vapors of liquid nitrogen for further
experiments.

- 201
- 202 Elispot assay

The frequency of T-cell-specific responses to the MVA-BN vaccine was assessed by Interferon- γ 203 ELISpot assay. Briefly, PBMC were thawed and suspended in a complete medium [RPMI-1640 added 204 205 of 10% FBS, 1% L-glutamine, and 1% penicillin/streptomycin (Euroclone S.p.A, Italy)]. Live PBMC were counted by Trypan blue exclusion, plated at 3x10⁵ cells per well in ELISpot plates (Human IFN-206 y ELISpot plus kit; Mabtech, Nacka Strand, Sweden), and stimulated for 20 h with MOI 1 of the 207 208 MVA-BN vaccine suspension [JYNNEOS (Smallpox and Monkeypox Vaccine, Live, nonreplicating)] and α CD28/ α CD49d (1 µg/ml, BD Biosciences) at 37 °C (5% CO₂), using T cell 209 superantigen (SEB 200 nM, Sigma) as positive control. At the end of the of incubation, the ELISpot 210 assay was developed following manufacturer's instructions. Results are expressed as spot-forming 211 cells per 10⁶ PBMCs (SFC/10⁶ PBMCs) in stimulating cultures after subtracting the background 212 213 (unstimulated culture).

214

215 *Statistical analysis*

Demographic and epidemiological characteristics of the patients are presented both for the overall
sample population and for each route of administration. Continuous variables were described using
median and Interquartile Range (IQR), while categorical variables were summarized using absolute
and relative (percentage) frequencies.

The main characteristics of participants according to the route of administration were compared usingthe Chi-square test or Fisher exact test when appropriate for qualitative variables and the Mann-

Whitney test for numerical variables. We then used collected diaries to calculate the prevalence of reported AEFIs according to the route of administration, as well as the duration and maximum level of severity ever experienced over the 28 days following the first dose of vaccination for each S-AEFI and LIS-AEFI, according to the above-mentioned grading (none to severe).

The raw proportions of participants whose maximum reported AEFIs was none, mild, moderate or 226 227 severe by route of administration groups are also shown. We also computed the Odds ratio (OR) of 228 the maximum severity level of AEFIs experienced by the administration route using multinomial 229 logistic regression models, both univariable and after adjusting for age and HIV status. In these 230 models, the never-reported AEFIs category was chosen as the reference group, and the estimated ORs 231 show the risk of reporting mild, moderate or severe AEFIs as the maximum level ever experienced according to the administration route. For a proportion of participants, the diary data were censored 232 at day six, so we have also performed a sensitivity analysis restricting to only the level of AEFI 233 234 severity ever experienced over the six days following the first vaccination dose for everybody.

As a second continuous outcome, we calculated the average number of days in which participants experienced each of the 4 levels of symptoms over the 28 days past the first dose of the MVA-BN vaccine. We then compared the average duration in days of any systemic or local reactions by route of administration by means of an unpaired t-test. Also, in this analysis, the comparison was performed by analyzing the reporting of any grade of reaction (from mild to severe, grade 1 to 3) or moderate to severe (2 or 3).

Similarly to what was done for the categorical outcome, we controlled for the potential confounding effect of age and HIV status using a counterfactual linear regression model and provided an estimate of the average treatment effect (ATE) associated with the administration route. Of note, the aim of this analysis was to evaluate what would have been the duration of any adverse response to the MVA-BN vaccine had everybody in the sample received the ID vs. had everybody received the SC route of administration instead. We used a doubly robust method (using augmented inverse probability weighting-AIPW) to obtain estimates which are robust against misspecification of either the

propensity model or the outcome model. Both the propensity and outcome models included HIV and 248 249 age as confounding variables. For the outcome model, we also used the saturated model, including the interaction parameter between exposure and HIV status (results were similar, not shown). 250 251 Finally, the same approach to analysis (a marginal model and the calculation of the ATE after controlling for HIV and age) was conducted in a subset of 171 (18%) vaccinated subjects for whom 252 253 stored samples were available and analyzed to compare the overall increase in the average levels (on 254 a log₂ scale) of IgG and nAb as well as ELISPOT response 1 month after vaccination according to 255 route of administration.

256

257 Results

258

259 *Characteristics of the study population*

Between August 8th and December 31st, 2022, 3,296 individuals received at least one dose of MVA-BN. Of those, 943 (28.6%) agreed to be enrolled in the study and completed the symptom-reporting daily diary covering their experience within 28 days from the first dose administration. Among the 943 individuals included in the analysis, 225 (23.9%) received the first dose via the SC route, of whom 50 as a single dose because they were vaccine-experienced (22.2% of this group), and 718 (76.1%) via the ID route; of this latter group 523 (73%) received only the first of the two doses scheduled for the previously unvaccinated.

All were male, and the majority (90.9%) self-identified as MSM. Overall, the median age was 44 years (IQR 36-51), 43 (36-48) years in the SC group, and 45 (38-52) years in the ID, respectively (p=0.15). Regarding other characteristics, 167 participants (17.7%) were on PrEP, 227 (24.1%) reported at least one STI diagnosed within the previous year, and 261 subjects (27.7%) were people living with HIV (PLWH), all on highly active antiretroviral therapy. HIV infection was more prevalent in the SC (35%) vs. the ID group (25%, p=0.0004). In those with HIV, CD4- cell count was lower than 200 cells/µL only in 10 participants (3.8%), while it was higher than 500 cells/µL in 211

274 (80.8%), with no evidence for a difference between the two groups (p=0.232). The two groups 275 differed significantly also according to the use of PrEP (25.8% vs. 15.2%, for SC and ID groups respectively, p<0.001) and in the proportion of participants who reported one or more comorbidities 276 277 (0% vs. 8.2%, for SC and ID group, respectively, p<0.001), while there was no evidence for a difference in other examined factors (i.e. sexual orientation, history of STI other than HIV, CD4 278 counts for those with HIV, and history of smallpox vaccination. The main characteristics of the study 279 280 population according to the administration route are reported in more detail in Table 1. The crude proportions of participants reporting various grades of the evaluated adverse effect are reported in 281 282 Figure 1 and Table 2. The grade and duration of S-AEFIs and LIS-AEFIs within 28 days from 283 vaccination according to the route of vaccination are summarized in Supplementary Figure 1.

284

285 Systemic reactions

No serious adverse events were observed over the 28-day follow-up. Overall systemic reactions occurred in 526 (55.9%) participants, with a higher proportion observed in the ID group compared to the SC group (59.1% vs 45.8%, p<0.001). The most common S-AEFIs were fatigue and headache, occurring in 46.7% and 33.8% of participants, which tended to be slightly higher in the ID group (p=0.08 and p=0.09, respectively); however, when considering only moderate or severe grades, there was no evidence for a difference between the two groups.

After adjusting for age and HIV status in a multinomial regression model, we found evidence that participants in the ID group had an increased risk of developing mild-grade headaches (2.91; 95% Confidence Interval, 95% CI: 1.23,6.89; p=0.045) compared to the SC group (Table 3). Results were similar when we restricted the analysis only to the first 6 days of the diary (OR=2.66, 95% CI:1.13-6.27, p=0.07), suggesting that most of the difference is likely to occur early after vaccination (Supplementary Table 1).

298 Systemic reactions were of short duration, 3.7 days on average for any grade and any type of S-AEFI,

- with no evidence for a difference in symptom duration between the ID and SC groups in theunadjusted analysis and after controlling for HIV and age (Table 4).
- 301 *Local reactions*

319

- LIS-AEFIs were reported by a total of 852 (90.9%) participants, with a higher proportion in those
 receiving the ID route (94.4% vs 80.0%, p<0.001).
- Among LIS-AEFIs, redness and induration at the injection site were the most frequently reported adverse effects (80.9% and 81.0%, respectively), with a significantly higher proportion (about twice as high) in the ID group than in the SC group (p<0.001); a similar difference was also observed considering only moderate or severe grade adverse events.
- In contrast, 74.7% of participants in the SC group reported any-grade pain at the injection site vs.
 69.2% in the ID group, although there was no evidence for a difference (p=0.14); the same applied
 when considering moderate or severe grade pain (34.2% vs. 30.1%, p=0.13).
- After controlling for HIV and age, we found a higher risk of occurrence for any grade of redness and induration at the local site in the ID than in the SC group (p<0.001). Conversely, a higher degree of pain was reported by participants who received the vaccine through the SC modality (p<0.002). ORs with 95% CI from fitting the multinomial regression models are reported in Table 3. Results were similar after restricting the analysis to the 0-6 days diary data (Supplementary Table 1).
- Local redness and induration (regardless of grade) were the most long-lasting symptoms, especiallyin the ID group (on average, 18.7 and 16.6 days in ID vs. 5.9 and 5.5 in the SC group, respectively).
- in the ID group (on average, 18.7 and 16.6 days in ID vs. 5.9 and 5.5 in the SC group, respectively).
- 318 After controlling for HIV status and age, we estimated that the duration of redness (regardless of
- p < 0.0001) longer than that of subjects receiving the SC strategy. Similar results were observed for

grade) in participants who received the vaccine in ID modality was 12.8 days (95% CI: 9.96, 15.55;

- inducation, which lasted on average 11.1 days (95% CI: 8.45, 13.7; p < 0.0001) longer in the ID vs.
- 322 SC strategy. After restricting the analysis to only moderate or severe grades, we observed a shorter
- duration of these AEFIs, although still significantly longer in the ID vs. SC group (7.14 vs. 4.24 days

for redness, p=0.023 and 5.55 vs. 3.23 days for induration, p=0.004). Overall, local pain (regardless of grade) had a shorter duration, not exceeding 7 days on average, but still with a longer duration in the ID vs. SC group (mean difference 1.8 days (95% CI: 0.2, 3.4; p=0.025) in the unadjusted analysis, which was however largely attenuated after considering only moderate and severe grade and controlling for age and HIV-status (p=0.312, Table 4).

329

330 Immunogenicity

Finally, in a subset of 171 (18%) vaccine recipients for whom samples have been stored and analyzed we compared the average change in immunogenicity one month after the completion of the vaccination cycle according to the route of administration (ID vs SC). Our counterfactual analysis controlling for HIV and age showed some evidence for a larger increase of MPXV-specific IgG (mean diff=0.26 log₂, p=0.05) and nAb (0.34 log₂, p=0.08) titers in favour of the ID vs. SC administration. Weaker evidence for a difference by administration route was found in the variation of MVA-BN specific T-cell response measured by Elispot assay (0.41, p=0.18) (Table 5).

338

339 Discussion

This work showed that the intradermal route of administration of the MVA-BN vaccine was safe and 340 341 well tolerated despite higher reactogenicity than the subcutaneous route. We did not observe serious adverse effects or syncope, as recently reported by the manufacturer¹¹. However, among the 342 participants receiving the vaccine ID, we observed a slightly higher prevalence of headache and 343 344 fatigue than in the SC group. This difference, already mild in the unadjusted analysis, was even more 345 mitigated after a multinomial analysis adjusted for age and HIV status. Local redness and induration 346 were confirmed to be more prevalent (94%) and long-lasting (around 18 days) among participants receiving the intradermal route than those receiving the subcutaneous one. On the contrary, pain was 347 more common after subcutaneous administration. These findings are quite expected considering the 348 349 mode of inoculation and are consistent with other reports. Recently, Frey et al. reported proportions

of adverse effects in people receiving the intradermal dose of 97% for the local and 79% for the systemic symptoms, without evidence of severe grade events. Moreover, local symptoms lasted over a month after the intradermal administration¹².

Although expected and not severe, redness and induration in the forearm were not well accepted by vaccinated people because they were considered a mark of vaccination and, consequently, of sexual behaviour associated with a high risk of contracting mpox.

356 Stigma could represent a barrier to vaccination, especially in countries where discrimination and 357 racism are deep-rooted, and the LGBT community is criminalized²⁶. Anyway, MVA-BN could also 358 be inoculated intradermally into the upper back just below the shoulder blade or into the skin of the 359 shoulder above the deltoid muscle²⁷, where the spot is less visible than in the forearm.

360 Knowledge of these aspects might help clinicians provide more appropriate counselling, make people 361 aware of the course of side effects, and, therefore, make vaccination more acceptable and widespread 362 enough to protect the "core group" that sustains the virus transmission and contributes to its possible 363 spread to the general population²⁸.

Regarding immunogenicity, our data collected one month after completing the vaccination cycle found a substantially equivalent immune response between the participants receiving the first dose intradermally and those receiving it subcutaneously. Differently from previously published data, analyzing humoral immune response against vaccinia virus VACV, not MPXV, we measured both titers of specific IgG and nAbs against MPXV, and we found that slightly higher titers of MPXV IgG and nAbs were elicited after the homologous (ID+ID) course of vaccination that after the heterologous (SC+ID) one.

These findings represent the immunological counterpart of a report from May 2022 to May 2024 in the USA, showing a higher incidence of breakthrough infections among people fully vaccinated with the heterologous than the homologous intradermal vaccination cycle. Of note, in our cohort, we did not observe breakthrough infections²⁹.

Finally, this is the first analysis providing data regarding the cellular immune response according to the administration route of MVA-BN. There was no evidence for a difference in the cellular immune response between participants receiving the first dose intradermally or subcutaneously.

T-cell response has been known to be crucial for the control and resolution of poxvirus infections^{30,31}, and T-cell reactivity to VACV and MPXV was detected decades post-vaccination with first-generation vaccine, suggesting a role of long-lasting cross-reactive T-cell memory responses in vaccine efficacy³². A good T-cell response was also demonstrated after third-generation MVA-BN³³. T-cells elicited from VACV-based vaccines were found to recognize MPXV-derived epitopes, suggesting that it is crucial for the cross-reactivity between different Orthopox strains³⁴. Consequently, T-cells could contribute to the recognition of the different MPXV clades and to a broader vaccine efficacy.

Recently, the Afro-Mpox bulletin showed a spreading outbreak involving several African countries, and clade Ib and clade IIb have been sequenced³⁵. In the wake of these reactogenicity and immunological data, we support the use of vaccination by MVA-BN administered by an intradermal route in low-income countries, as WHO suggested, even still in the absence of specific data against the clade Ib. Thus, the sparing-dose protocol of ID-based vaccination may provide a cost-effective approach to the current global vaccination campaign.

Some limitations need to be stated. First, the study's observational design could account for unmeasured bias, although the analysis was controlled for the main confounders. Furthermore, we cannot compare the two homologous cycles (SC+SC vs ID+ID) because the second doses were only administered intradermally due to the regulatory recommendations. For this reason, we have limited the comparison to the first dose. As mentioned, although we extensively assessed the immune response against MPXV clade IIb, we cannot provide information on the humoral and cellular response against Clade I.

398

In conclusion, our study demonstrated that the intradermal route of administration of MVA-BNelicited slightly higher titers of MPXV-specific IgG and nAbs than the subcutaneous route. At the

- same time, no differences in cellular response were detected. MVA-BN was globally well tolerated
 despite higher reactogenicity with the intradermal than the subcutaneous route. Based on these results,
 we believe that intradermal administration of MVA-BN is feasible, safe, and immunogenic, and we
 support the use of this dose-sparing strategy to increase the feasibility of a broad vaccination
 campaign to control the current multiclade mpox outbreak in Africa.
- 407

408 Acknowledgements

409 We thank the participants who gave their time to the project, the nurse, the laboratory staff, and the bio-banking personnel. Thanks to all the members of the Mpox Vaccine Lazio Study Group: C 410 411 Aguglia, A Antinori, E Anzalone, A Barca, M Camici, F Cannone, P Caputi, R Casetti, L Caterini, C Cimaglia, E Cimini, F Colavita, L Coppola, R Corso, F Cristofanelli, S Cruciani, N De Marco, G Del 412 413 Duca, G D'Ettorre, S Di Bari, S Di Giambenedetto, P Faccendini, F Faraglia, D Farinacci, A Faticoni, 414 C Fontana, M Fusto, R Gagliardini, P Gallì, S Gebremeskel, G Giannico, S Gili, E Girardi, G Grassi, MR Iannella, A Junea, D Kontogiannis, A Lamonaca, S Lanini, A Latini, D Lapa, M Lichtner, MG 415 416 Loira, F Maggi, A Marani, M Marchili, R Marocco, A Masone, C Mastroianni, I Mastrorosa, G 417 Matusali, V Mazzotta, S Meschi, S Minicucci, A Mondi, V Mondillo, A Nappo, G Natalini, E Nicastri, S Notari, A Oliva, A Parisi, J Paulicelli, C Pinnetti, P Piselli, MM Plazzi, A Possi, G Preziosi, R 418 419 Preziosi, G Prota, M Ridolfi, S Rosati, A Russo, L Sarmati, P Scanzano, L Scorzolini, C Stingone, E 420 Tamburrini, E Tartaglia, V Tomassi, F Vaia, A Vergori, M Vescovo, S Vita, J Volpi, P Zuccalà.

421

422 Authors contribution

423 VM, AA, and ACL conceived the study; VM, GMa, EC, and FC wrote the protocol. PP and VM wrote the first draft of the manuscript. AA, FM, ACL, EC, GMa, FC, EG, EN, CF and CA revised the 424 425 manuscript. GMa, FC, SM, LB, SN, RC, and GG performed the laboratory analyses. PP, JP, AC and CC was responsible for data management. PP and ACL performed statistical analysis. VM, RE, AG, 426 427 GMi, AO, SG, and RG enrolled and followed the patients during the study time points. ML, LS, ET, 428 CM, and AL contributed to the enrollment. PG, AS, FV, and AB contributed to the realization of the 429 study. VM and AA provided the grant for funding the study. All authors gave their final approval of the submitted version. 430

431

432

433 **Competitive of interests**

- 434 AA received a grant from Bavarian Nordic for participation in conferences. The other authors
- 435 declared no conflicts of interest.
- 436

437 Data sharing statement

- 438 Data are available upon reasonable request from the corresponding author.
- 439

440 Funding

- 441 The study was supported by the National Institute for Infectious Disease Lazzaro Spallanzani IRCCS
- 442 "Advanced grant 5x1000, 2021" and by the Italian Ministry of Health "Ricerca Corrente Linea 2"
- 443 INMI Spallanzani IRCCS

444 References

464

8.

- 1. Centers for Disease Control and Prevention. 2022 2023 Monkeypox Outbreak Global Map.
- 446 2023. https://www.cdc.gov/poxvirus/mpox/response/2022/world-map.html (2024).
- 447 2. World Health Organization. WHO director general declares the ongoing monkeypox outbreak
- 448 a public health event of international concern. https://www.who.int/europe/news/item/23-07-
- 449 2022-who-director-general-declares-the-ongoing-monkeypox-outbreak-a-public-health-event-
- 450 of-international-concern (2022).
- 451 3. Hubach, R. D. & Owens, C. Findings on the Monkeypox Exposure Mitigation Strategies
- 452 Employed by Men Who Have Sex with Men and Transgender Women in the United States.
- 453 Arch. Sex. Behav. 51, 3653–3658 (2022).
- 454 4. European Medicines Agency. EMA recommends approval Imvanex prevention monkeypox
- disease. https://www.ema.europa.eu/en/news/ema-recommends-approval-imvanex-
- 456 prevention-monkeypox-disease (2022).
- 457 5. Food and Drug Administration. BLA approval.
- 458 https://www.fda.gov/media/131079/download?attachment (2019).
- 459 6. Frey, S. E. et al. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA)
- 460 formulations and subcutaneous versus intradermal routes of administration in healthy
 461 vaccinia-naïve subjects. *Vaccine* 33, 5225–5234 (2015).
- Frey, S. E., Goll, J. B. & Beigel, J. H. Erythema and Induration after Mpox (JYNNEOS)
 Vaccination Revisited. *N. Engl. J. Med.* 388, 1432–1435 (2023).
- (2023)
- 465 Monkeypox Benefits for Individual and Public Health. N. Engl. J. Med. 387, 1151–1153
 466 (2022).

Brooks, J. T., Marks, P., Goldstein, R. H. & Walensky, R. P. Intradermal Vaccination for

- 467 9. European Medicines Agency. EMA's Emergency Task Force advises on intradermal use of
- 468 Imvanex / Jynneos against monkeypox. https://www.ema.europa.eu/en/news/emas-
- 469 emergency-task-force-advises-intradermal-use-imvanex-jynneos-against-monkeypox.

- 470 10. Food and Drug Administration. Review Memorandum for the emergency use authorization
- 471 (EUA) of JYNNEOS. https://www.fda.gov/media/160785/download.
- 472 11. Weidenthaler, H., Vidojkovic, S., Martin, B. K. & Moerlooze, L. D. Real-world safety data for
- 473 MVA-BN: Increased frequency of syncope following intradermal administration for
- immunization against mpox disease. *Vaccine* (2024) doi:10.1016/j.vaccine.2024.05.072.
- 475 12. Frey, S. E., Lerner, A. & Tomashek, K. Safety and immunogenicity of fractional doses of

476 Modified Vaccinia Ankara-Bavarian Nordic. in (ESCMID Global, 2024).

- 477 13. Dalton, A. F. et al. Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A
- 478 Multijurisdictional Case-Control Study United States, August 19, 2022–March 31, 2023.
- 479 *MMWR Morb. Mortal. Wkly. Rep.* **72**, 553–558 (2023).
- 480 14. Vairo, F. *et al.* The possible effect of sociobehavioral factors and public health actions on the
 481 mpox epidemic slowdown. *Int. J. Infect. Dis.* 130, 83–85 (2023).
- 482 15. World Health Organization. Weekly Bulletin on Outbreak and Other Emergencies: Week 28: 8
 483 14 July 2024. https://iris.who.int/handle/10665/378355.
- Vakaniaki, E. H. *et al.* Sustained human outbreak of a new MPXV clade I lineage in eastern
 Democratic Republic of the Congo. *Nat. Med.* (2024) doi:10.1038/s41591-024-03130-3.
- 486 17. World Health Organization. WHO Director-General declares mpox outbreak a public health
- 487 emergency of international concern. https://www.who.int/news/item/14-08-2024-who-
- 488 director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-
- 489 concern.
- 490 18. Kibungu, E. M. *et al.* Clade I–Associated Mpox Cases Associated with Sexual Contact, the
 491 Democratic Republic of the Congo. *Emerg. Infect. Dis.* 30, (2024).
- 492 19. Kozlov, M. Growing mpox outbreak prompts WHO to declare global health emergency.
- 493 *Nature* (2024) doi:10.1038/d41586-024-02607-y.
- 494 20. Ministero della Salute. Circolare del Ministero della Salute n. 35365 Indicazioni ad interim
 495 sulla strategia vaccinale contro il vaiolo delle scimmie (MPX). (2022).

496 21. Istituto Superiore Di Sanita'. EpiCentro sul vaiolo. https://www.epicentro.iss.it/vaiolo/.

497 (2022).

498 22. Ministero della Salute. Aggiornamento sulla modalità di somministrazione del vaccino

499 JYNNEOS (MVA-BN).

- 500 23. Mazzotta, V. et al. Immunogenicity and reactogenicity of modified vaccinia Ankara pre-
- 501 exposure vaccination against mpox according to previous smallpox vaccine exposure and

502 HIV infection: prospective cohort study. *eClinicalMedicine* **68**, 102420 (2024).

503 24. Food and Drug Administration. Guidance for industry - Toxicity Grading Scale for Healthy

Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.

505 https://www.fda.gov/media/73679/download (2007).

- 506 25. Colavita, F. *et al.* Kinetics of viral DNA in body fluids and antibody response in patients with
 acute Monkeypox virus infection. *iScience* 26, 106102 (2023).
- 508 26. World Health Organization. WHO publishes public health advice on preventing and
- addressing stigma and discrimination related to mpox. https://www.who.int/news/item/11-12-
- 510 2022-who-publishes-public-health-advice-on-preventing-and-addressing-stigma-and-
- 511 discrimination-related-to-mpox (2022).
- 512 27. Centers for Disease Control and Prevention. Mpox Vaccine Recommendations.
- 513 https://www.cdc.gov/poxvirus/mpox/vaccines/vaccine-recommendations.html (2024).
- 514 28. Allan-Blitz, L.-T. & Klausner, J. D. Prevalence of mpox immunity among the core group and
- 515 its potential to prevent future large-scale outbreaks. *Lancet Microbe* 100957 (2024)

516 doi:10.1016/j.lanmic.2024.100957.

- 517 29. Guagliardo, S. A. J. et al. Monkeypox Virus Infections After 2 Preexposure Doses of
- 518 JYNNEOS Vaccine United States, May 2022–May 2024. MMWR Morb. Mortal. Wkly.
- 519 *Rep.* **73**, 460–466 (2024).
- 520 30. Pauli, Georg *et al.* Orthopox Viruses: Infections in Humans. *Transfus. Med. Hemotherapy* 37,
 521 351–364 (2010).

522 31. Jing, L. *et al.* Diversity in the Acute CD8 T Cell Response to Vaccinia Virus in Humans1,2.

523 (2007).

- 524 32. Matusali, G. *et al.* Evaluation of Cross-Immunity to the Mpox Virus Due to Historic Smallpox
 525 Vaccination. *Vaccines* 11, 1541 (2023).
- 526 33. Cohn, H. *et al.* Mpox vaccine and infection-driven human immune signatures: an
- 527 immunological analysis of an observational study. *Lancet Infect. Dis.* **23**, 1302–1312 (2023).
- 528 34. Crandell, J. et al. The impact of antigenic distance on Orthopoxvirus Vaccination and Mpox

529 Infection for cross-protective immunity. doi:10.1101/2024.01.31.24302065.

- 530 35. World Health Organization. Regional Office for Africa. Regional Mpox Bulletin: 11 August
- 531 2024. https://iris.who.int/handle/10665/378456 (2024).

532

			Route of administration of the first vaccination dose			
Characteristics		Total N= 943	ID N= 718	SC N= 225	p-value [*]	
Sexual orientation, n (%)	Bisexual	65 (6.9)	52 (7.2)	13 (5.8)	0.479	
	Transgender	12 (1.3)	9 (1.3)	3 (1.3)		
	MSM	857 (90.9)	648 (90.3)	209 (92.9)		
Age, years	Median (IQR)	44 (36, 51)	45 (38, 52)	43 (36, 48)	0.153	
PrEP use, n (%)	No	759 (80.5)	604 (84.1)	155 (68.9)	< 0.001	
	Yes	167 (17.7)	109 (15.2)	58 (25.8)		
	Not reported	15 (1.6)	4 (0.6)	11 (4.9)		
>=1 STI over previous year, n (%)	Yes	227 (24.1)	161 (22.5)	66 (29.3)	0.286	
	Syphilis	108 (57.4)	72 (55.0)	36 (63.2)	0.222	
	Gonorrhoea	73 (39.9)	44 (34.9)	29 (50.9)	0.329	
	Chlamydia	43 (24.6)	22 (18.6)	21 (36.8)	0.324	
	HPV	28 (16.4)	14 (12.3)	14 (24.6)	0.298	
	PLWH	261 (27.7)	182 (25.3)	79 (35.1)	0.004	
	PLWH on effective ART	261 (100.0)	182 (100.0)	79 (100.0)		
CD4 cell count ^{&} , cells/mm ³ , n (%)	0-200	10 (3.8)	5 (2.7)	5 (6.3)	0.232	
	201-500	39 (14.9)	28 (15.4)	11 (13.9)		
	501+	211 (80.8)	149 (81.9)	62 (78.5)		
	Unknown	1 (0.4)	0 (0.0)	1 (1.3)		
Comorbidities, n (%)	None	884 (93.7)	659 (91.8)	225 (100.0)	< 0.001	
	>=1	37 (3.9)	37 (5.2)	0 (0.0)		
	Unknown	22 (2.3)	22 (3.1)	0 (0.0)		
Previous smallpox vaccination, n (%)	Yes	245 (26.0)	195 (27.2)	50 (22.2)	0.638	

Table 1. Main characteristics by route of administration of the first MVA-BN dose.

*In PLWH; *Chi-square or Mann-Whitney test as appropriate ID: intradermal; SC: subcutaneous; MSM: men who have sex with men; IQR: interquartile range; PrEP: pre-exposure prophylaxis for HIV infection; STI: sexually transmitted infection; HPV: human papillomavirus; PLWH: people living with HIV; ART: antiretroviral therapy.

			Prevalence of symptoms (ID vs. SC)		
Adverse effect	Grade	Tot n (%)	ID n (%)	SC n (%)	p-value*
Any S-AEFI	No	415 (44.1)	293 (40.9)	122 (54.2)	
	Yes, any grade	526 (55.9)	423 (59.1)	103 (45.8)	< 0.001
Fatigue	No	502 (53.3)	370 (51.7)	132 (58.7)	
0	Yes, any grade	439 (46.7)	346 (48.3)	93 (41.3)	0.079
	Yes, moderate or severe	221 (23.5)	163 (22.8)	58 (25.8)	0.938
Headache	No	623 (66.2)	463 (64.7)	160 (71.1)	
	Yes, any grade	318 (33.8)	253 (35.3)	65 (28.9)	0.089
	Yes, moderate or severe	128 (13.6)	92 (12.8)	36 (16)	0.644
Myalgia	No	708 (75.2)	541 (75.6)	167 (74.2)	
	Yes, any grade	233 (24.8)	175 (24.4)	58 (25.8)	0.752
	Yes, moderate or severe	97 (10.3)	71 (9.9)	26 (11.6)	0.569
Nausea	No	823 (87.5)	626 (87.4)	197 (87.6)	
	Yes, any grade	118 (12.5)	90 (12.6)	28 (12.4)	0.948
	Yes, moderate or severe	42 (4.5)	30 (4.2)	12 (5.3)	0.617
Chills	No	835 (88.7)	639 (89.2)	196 (87.1)	
	Yes, any grade	106 (11.3)	77 (10.8)	29 (12.9)	0.446
	Yes, moderate or severe	47 (5)	34 (4.7)	13 (5.8)	0.631
Vomit	No	915 (97.2)	697 (97.3)	218 (96.9)	
,	Yes, any grade	26 (2.8)	19 (2.7)	7 (3.1)	0.895
	Yes, moderate or severe	11 (1.2)	8 (1.1)	3 (1.3)	0.999
Any LIS-AEFI	No	85 (9.1)	40 (5.6)	45 (20.0)	
	Yes, any grade	852 (90.9)	672 (94.4)	180 (80.0)	< 0.001
Redness	No	179 (19.1)	42 (5.9)	137 (60.9)	0.001
neuness	Yes, any grade	758 (80.9)	670 (94.1)	88 (39.1)	< 0.001
	Yes, moderate or severe	556 (59.3)	511 (71.8)	45 (20.0)	< 0.001
Induration	No	178 (19.0)	59 (8.3)	119 (52.9)	0.001
	Yes, any grade	759 (81.0)	653 (91.7)	106 (47.1)	< 0.001
	Yes, moderate or severe	450 (48.0)	396 (55.6)	54 (24.0)	< 0.001
Pain	No	276 (29.5)	219 (30.8)	57 (25.3)	
	Yes, any grade	661 (70.5)	493 (69.2)	168 (74.7)	0.141
	Yes, moderate or severe	291 (31.1)	214 (30.1)	77 (34.2)	0.127

 Table 2. Table of prevalence of Systemic and Local Adverse Effects Following Immunisation (S-AEFIs and L-AEFIs) with MVA-BN Vaccine.

*Chi-square or Fisher's exact test as appropriate, comparing No vs Yes, any grade or No vs Yes, moderate or severe.

Table 3. Prevalence and risk of developing different grades of Systemic and Local Adverse Effects Following Immunisation (S-AEFIs and L-AEFIs) with MVA-BN Vaccine from fitting a multinomial logistic regression according to administration route - intradermal (ID) vs subcutaneous (SC).

		Prevalence of S-AEFIs and OR (ID vs. SC)						
Systemic symptoms	max severity	ID n (%)	SC n (%)	Unadjusted OR (95% CI) ID vs. SC	p-value	Adjusted* OR (95% CI) ID vs. SC	p-value	
Fatigue	None	370 (51.7)	132 (58.7)	1	< 0.001	1	0.673	
	Mild	183 (25.6)	35 (15.6)	1.87 (1.23, 2.82)		0.95 (0.40, 2.24)		
	Moderate	120 (16.8)	30 (13.3)	1.43 (0.91, 2.23)		1.67 (0.66, 4.26)		
	Severe	43 (6.0)	28 (12.4)	0.55 (0.33, 0.92)		1.54 (0.49, 4.81)		
Headache	None	463 (64.7)	160 (71.1)	1	0.011	1	0.045	
	Mild	161 (22.5)	29 (12.9)	1.92 (1.24, 2.96)		2.91 (1.23, 6.89)		
	Moderate	68 (9.5)	25 (11.1)	0.94 (0.57, 1.54)		1.37 (0.44, 4.27)		
	Severe	24 (3.4)	11 (4.9)	0.75 (0.36, 1.57)		7.17 (0.74, 69.81)		
Myalgia	None	541 (75.6)	167 (74.2)	1	0.915	1	0.675	
	Mild	104 (14.5)	32 (14.2)	1.00 (0.65, 1.55)		1.04 (0.39, 2.78)		
	Moderate	45 (6.3)	17 (7.6)	0.82 (0.46, 1.47)		1.27 (0.37, 4.32)		
	Severe	26 (3.6)	9 (4.0)	0.89 (0.41, 1.94)		2.47 (0.57, 10.68)		
Nausea	None	626 (87.4)	197 (87.6)	1	0.294	1	0.723	
	Mild	60 (8.4)	16 (7.1)	1.18 (0.66, 2.10)		1.79 (0.50, 6.46)		
	Moderate	17 (2.4)	10 (4.4)	0.53 (0.24, 1.19)		0.55 (0.10, 3.13)		
	Severe	13 (1.8)	2 (0.9)	Nd		Nd		
Chills	None	639 (89.2)	196 (87.1)	1	0.089	1	0.698	
	Mild	43 (6.0)	16 (7.1)	0.82 (0.45, 1.50)		1.13 (0.37, 3.50)		
	Moderate	20 (2.8)	12 (5.3)	0.51 (0.25, 1.06)		0.27 (0.03, 2.48)		
	Severe	14 (2.0)	1 (0.4)	Nd		Nd		
Vomit	None	697 (97.3)	218 (96.9)	1	0.195	1	0.748	
	Mild	11 (1.5)	4 (1.8)	0.86 (0.27, 2.73)		2.68 (0.21, 33.94)		
	Moderate	3 (0.4)	3 (1.3)	Nd		Nd		
	Severe	5 (0.7)	0 (0.0)	Nd		Nd		
		Prevalence of L-AEFIs and OR (ID vs. SC)						
Local symptoms	max severity	ID n (%)	SC n (%)	Unadjusted OR (95% CI) ID vs. SC	p-value	Adjusted* OR (95% CI) ID vs. SC	p-value	
Redness	None	42 (5.9)	137 (60.9)	1	0.089	1	< 0.001	
	Mild	159 (22.3)	43 (19.1)	12.06 (7.44, 19.54)		26.87 (6.87, 105.1)		

	Moderate Severe	328 (46.1) 183 (25.7)	25 (11.1) 20 (8.9)	42.80 (25.10, 72.98) 29.85 (16.77, 53.13)		65.91 (16.39, 265.1) 48.44 (11.71, 200.4)	
Induration	None Mild Moderate Severe	59 (8.3) 257 (36.1) 292 (41.0) 104 (14.6)	119 (52.9) 52 (23.1) 37 (16.4) 17 (7.6)	1 9.97 (6.47, 15.35) 15.92 (10.02, 25.29) 12.34 (6.77, 22.49)	<0.001	1 12.08 (4.44, 32.89) 14.92 (5.03, 44.22) 16.28 (4.73, 55.98)	<0.001
Pain	None Mild Moderate Severe	219 (30.8) 279 (39.2) 165 (23.2) 49 (6.9)	57 (25.3) 91 (40.4) 60 (26.7) 17 (7.6)	$1 \\ 0.80 (0.55, 1.16) \\ 0.72 (0.47, 1.08) \\ 0.75 (0.40, 1.40)$	0.425	1 0.36 (0.16, 0.81) 0.14 (0.05, 0.39) 0.57 (0.15, 2.18)	0.002

* Adjusted for age and HIV status. 95% CI: 95% Confidence Interval

Nd: not determined

Table 4. Contrasts of the duration of Systemic and Local Adverse Effects Following Immunisation (S-AEFIs and L-AEFIs) with MVA-BN

	Potential average duration of systemic symptoms (days) over 1-28 days after the 1 st vaccine dose						
	Mean in ID (95% CI)	Mean in SC (95% CI)	ATE [*] (95% CI) ID vs. SC	p-value			
S-AEFIs							
Fatigue - any	3.70 (2.63, 4.77)	3.46 (2.21, 4.72)	0.24 (-1.36, 1.84)	0.7720			
Fatigue - moderate or severe	2.95 (1.26, 4.63)	3.03 (1.07, 4.98)	-0.08 (-2.52, 2.36)	0.9488			
Headache - any	2.20 (1.53, 2.87)	2.51 (1.81, 3.20)	-0.30 (-1.24, 0.63)	0.5269			
Headache - moderate or severe	2.53 (0.99, 4.07)	2.20 (1.23, 3.16)	0.34 (-1.37, 2.04)	0.7005			
Myalgia - any	3.65 (2.11, 5.19)	3.12 (2.14, 4.10)	0.52 (-1.21, 2.25)	0.5527			
Myalgia - moderate or severe	3.20 (0.51, 5.90)	2.17 (0.71, 3.63)	1.03 (-1.64, 3.70)	0.4479			
Nausea - any	3.31 (1.61, 5.00)	1.74 (1.17, 2.30)	1.57 (-0.09, 3.22)	0.0632			
Chills - any	2.10 (1.32, 2.88)	1.92 (1.07, 2.77)	0.18 (-0.85, 1.21)	0.7289			
L-AEFIs							
Redness - any	18.66 (16.76, 20.55)	5.90 (3.72, 8.09)	12.76 (9.96, 15.55)	< 0.0001			
Redness - moderate or severe	7.14 (5.61, 8.66)	4.24 (2.06, 6.42)	2.90 (0.41, 5.39)	0.0226			
Induration - any	16.62 (14.51, 18.73)	5.54 (3.66, 7.41)	11.09 (8.45, 13.72)	<0.0001			
Induration - moderate or severe	5.55 (4.08, 7.02)	3.23 (2.66, 3.81)	2.32 (0.75, 3.89)	0.0037			
Pain - any	6.18 (4.66, 7.70)	4.37 (3.86, 4.88)	1.81 (0.22, 3.39)	0.0254			
Pain - moderate or severe	4.77 (1.69, 7.85)	3.13 (2.54, 3.72)	1.64 (-1.54, 4.82)	0.3124			

Vaccine (days 1-28 after 1st dose) and ATE[&] from fitting a linear regression model.

[&]Average Treatment Effect ^{*}weighted for age and HIV status

Table 5. Potential average change one month after the completion of vaccination cycle according to the route of administration of the first dose and ATE[&] from fitting a linear regression model (log₂ scale)

	Mean (log2) in ID (95% CI)	Mean (log2) in SC (95% CI)	ATE* (95% CI)	p-value
Elispot	1.74 (1.31, 2.17)	1.33 (0.94, 1.73)	0.41 (-0.19, 1.01)	0.183
IgG	1.22 (1.00, 1.43)	0.96 (0.80, 1.13)	0.26 (-0.00, 0.51)	0.053
nAbs	0.84 (0.53, 1.16)	0.50 (0.28, 0.72)	0.34 (-0.04, 0.72)	0.076

[&]Average Treatment Effect; ^{*}weighted for age and HIV-status

Figure 1. Distribution of reactivity and referred severity of Systemic and Local Injection Site Adverse Effect Following Immunisation (S-AEFIs and LIS-AEFIs) with the first dose of MVA-BN Vaccine within 28-days from vaccination according to route of administration [All: N=943; Sub-cutaneous (SC): N=225; Intra-dermal (ID): N=718]. p<0.10 are shown; p values refer to the difference in the proportion of any grade symptom between the SC and ID groups.

